Prostate Cancer: A031201 (Hematology Oncology Associates)

Alliance A031201: Phase III Trial of Enzalutamide (NSC #766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer


The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone, and enzalutamide with enzalutamide alone on patients that have prostate cancer that has spread and has not responded to hormonal therapy to find out which is better.

Doctors are uncertain about what is the best way to treat castration resistant prostate cancer (CRPC). In this study, patients will get either the combination of abiraterone, prednisone, and enzalutamide or enzalutamide alone.

Abiraterone and enzalutamide are both hormonal agents approved by the Food and Drug Administration for patients with castration-resistant metastatic disease. Each drug works in a different way to block hormones. Abiraterone and enzalutamide are both highly effective drugs in blocking hormones in men with CRPC. Abiraterone has recently received FDA approval for patients who have not received chemotherapy, such those patients eligible for this study.

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Prostate Cancer
Alliance for Clinical Trials in Oncology
Katy D'Aprile, RN, BSN at 563-355-7733


  • University of Iowa Hospital & Clinics, Cancer Center of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office